The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.




Oncoceutics ONC201 - $83,333

Amount
$83,333.00
Date
October 2018

Expansion of the ONC201 Compassionate Use.

The Institute of Cancer Research - $100,000

Amount
$100,000.00
Date
October 2018

Short-pulse Ultrasound Delivery of Panobinostat for the Treatment of Diffuse Intrinsic Gliomas in Children

The Institute of Cancer Research - $106,647

Amount
$106,647.00
Date
October 2018

A Mouse Model of HIST1H3B/ACVR1 Mutant DIPG.

Johns Hopkins Children's Center - $50,000

Amount
$50,000.00
Date
July 2018

Using Zebrafish to Accelerate DIPG Drug Development.

Funding of PBTCF 2018: PBTC-058 - $16,800

Amount
$16,800.00
Date
January 2018

PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma

The Campbell Family Institute for Cancer Research - $100,000

Amount
$100,000.00
Date
October 2017

Defining the molecular mechanisms of DIPG development and progression to uncover novel therapeutic targets

Institute of Cancer Research - $102,432

Amount
$102,432.00
Date
October 2017

Combinational strategies alongside ACVR1 inhibition in DIPG

The Regents of the University of California - $70,000

Amount
$70,000.00
Date
October 2017

An Open Label Single Arm Phase I/II study of MTX110 delivered by convection-enhanced delivery (CED) in patients with diffuse intrinsic pontine glioma (DIPG) previously treated with external beam radiation therapy

The Hospital for Sick Children - $100,560

Amount
$100,560.00
Date
October 2017

MRI Guided Focused Ultrasound: Towards Clinical Translation in Diffuse Intrinsic Pontine Glioma (DIPG)

Texas Children's Hospital and Ann & Robert H. Lurie Children's Hospital of Chicago - $200,000

Amount
$200,000.00
Date
October 2017

Targeting DIPG through Combining a Super-activator (MCB-613) of Steroid Receptor Co-activators with Radiation.

Gustave Roussy - $101,868

Amount
$101,868.00
Date
October 2017

Elucidating the underlying mechanisms of radio resistance at diagnosis and relapse in DIPG

Ospedale Pediatrico Bambino Gesu - $98,987

Amount
$98,987.00
Date
October 2017

Investigating the role of DIPG-derived exosomes in tumor growth and invasion

Memorial Sloan Kettering Cancer Center - $100,000

Amount
$100,000.00
Date
October 2017

Targeting EZH2 as a therapeutic strategy in DIPG

Dana-Farber Cancer Institute - $82,863

Amount
$82,863.00
Date
October 2017

Defining the Cellular Architecture of Diffuse Intrinsic Pontine Glioma through Large-Scale Single-cell RNA-sequencing analyses

The Hospital of Sick Children - $162,828

Amount
$162,828.00
Date
October 2017

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: an in vitro and in vivo preclinical study